(UroToday.com) Targeted therapy has significantly changed the treatment landscape for renal cell carcinoma, and more recently, immuno-oncology–based combinations have also made a significant impact. Treatment choice in advanced renal cell carcinoma (aRCC) is informed by patient risk, as measured by the validated International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model. This model categorizes patients into favorable (F), intermediate (I), and poor (P) risk groups according to prognosis1.